Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Neuropediatrics ; 55(1): 23-31, 2024 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-37871611

RESUMEN

BACKGROUND: Neonatal hypoxic-ischemic brain injury (HIBI) results from disruptions to blood supply and oxygen in the perinatal brain. The goal of this study was to measure brain sterol metabolites and plasma oxysterols after injury in a neonatal HIBI mouse model to assess for potential therapeutic targets in the brain biochemistry as well as potential circulating diagnostic biomarkers. METHODS: Postnatal day 9 CD1-IGS mouse pups were randomized to HIBI induced by carotid artery ligation followed by 30 minutes at 8% oxygen or to sham surgery and normoxia. Brain tissue was collected for sterol analysis by liquid chromatography with tandem mass spectrometry (LC-MS/MS). Plasma was collected for oxysterol analysis by LC-MS/MS. RESULTS: There were minimal changes in brain sterol concentrations in the first 72 hours after HIBI. In severely injured brains, there was a significant increase in desmosterol, 7-DHC, 8-DHC, and cholesterol 24 hours after injury in the ipsilateral tissue. Lanosterol, 24-dehydrolathosterol, and 14-dehydrozymostenol decreased in plasma 24 hours after injury. Severe neonatal HIBI was associated with increased cholesterol and sterol precursors in the cortex at 24 hours after injury. CONCLUSIONS: Differences in plasma oxysterols were seen at 24 hours but were not present at 30 minutes after injury, suggesting that these sterol intermediates would be of little value as early diagnostic biomarkers.


Asunto(s)
Hipoxia-Isquemia Encefálica , Oxiesteroles , Animales , Ratones , Animales Recién Nacidos , Biomarcadores/metabolismo , Encéfalo , Colesterol/metabolismo , Colesterol/farmacología , Colesterol/uso terapéutico , Cromatografía Liquida , Hipoxia-Isquemia Encefálica/terapia , Oxígeno/metabolismo , Oxígeno/farmacología , Oxígeno/uso terapéutico , Oxiesteroles/metabolismo , Oxiesteroles/farmacología , Oxiesteroles/uso terapéutico , Espectrometría de Masas en Tándem , Modelos Animales de Enfermedad , Distribución Aleatoria
2.
J Atheroscler Thromb ; 30(8): 907-918, 2023 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-36450458

RESUMEN

AIM: Several clinical trials using intravascular ultrasound (IVUS) evaluation have demonstrated that intensive lipid-lowering therapy by statin or a combination therapy with statin and ezetimibe results in significant regression of coronary plaque volume. However, it remains unclear whether adding ezetimibe to statin therapy affects coronary plaque composition and the molecular mechanisms of plaque regression. We conducted this prospective IVUS analysis in a subgroup from the CuVIC trial. METHODS: The CuVIC trial was a prospective randomized, open, blinded-endpoint trial conducted among 11 cardiovascular centers, where 260 patients with coronary artery disease who received coronary stenting were randomly allocated into either the statin group (S) or the combined statin and ezetimibe group (S+E). We enrolled 79 patients (S group, 39 patients; S+E group, 40 patients) in this substudy, for whom serial IVUS images of nonculprit lesion were available at both baseline and after 6-8 months of follow-up. RESULTS: After the treatment period, the S+E group had significantly lower level of low-density lipoprotein cholesterol (LDL-C; 80.9±3.7 vs. 67.7±3.8 mg/dL, p=0.0143). Campesterol, a marker of cholesterol absorption, and oxysterols (ß-epoxycholesterol, 4ß-hydroxycholesterol, and 27-hydroxycholesterol) were also lower in the S+E group. IVUS analyses revealed greater plaque regression in the S+E group than in the S group (-6.14% vs. -1.18% for each group, p=0.042). It was noteworthy that the lowering of campesterol and 27-hydroxycholesterol, but not LDL-C, had a significant positive correlation with plaque regression. CONCLUSIONS: Compared with statin monotherapy, ezetimibe in combination with statin achieved significantly lower LDL-C, campesterol, and 27-hydroxycholesterol, which resulted in greater coronary plaque regression.


Asunto(s)
Anticolesterolemiantes , Enfermedad de la Arteria Coronaria , Inhibidores de Hidroximetilglutaril-CoA Reductasas , Oxiesteroles , Placa Aterosclerótica , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Ezetimiba/uso terapéutico , Anticolesterolemiantes/uso terapéutico , Oxiesteroles/uso terapéutico , Estudios Prospectivos , Quimioterapia Combinada , Placa Aterosclerótica/tratamiento farmacológico , Colesterol , Resultado del Tratamiento
3.
Eur J Pharmacol ; 934: 175299, 2022 Nov 05.
Artículo en Inglés | MEDLINE | ID: mdl-36181780

RESUMEN

Cataract is the leading cause of blindness worldwide. Cataract phacoemulsification combined with intraocular lens implantation causes great burden to global healthcare, especially for low- and middle-income countries. Such burden would be significantly relieved if cataracts can effectively be treated or delayed by non-surgical means. Excitingly, novel drugs have been developed to treat cataracts in recent decades. For example, oxysterols are found to be able to innovatively reverse lens clouding, novel nanotechnology-loaded drugs improve anti-cataract pharmacological effect, and traditional Chinese medicine demonstrates promising therapeutic effects against cataracts. In the present review, we performed bibliometric analysis to provide an overview perspective regarding the research status, hot topics, and academic trends in the field of anti-cataract pharmacology therapy. We further reviewed the curative effects and molecular mechanisms of anti-cataract drugs such as lanosterol, metformin, resveratrol and curcumin, and prospected the possibility of their clinical application in future.


Asunto(s)
Catarata , Curcumina , Metformina , Oxiesteroles , Humanos , Lanosterol/farmacología , Resveratrol/uso terapéutico , Curcumina/uso terapéutico , Catarata/tratamiento farmacológico , Catarata/etiología , Oxiesteroles/uso terapéutico , Bibliometría , Metformina/uso terapéutico
4.
Elife ; 112022 09 16.
Artículo en Inglés | MEDLINE | ID: mdl-36111785

RESUMEN

Defective 3ß-hydroxysterol-Δ7 -reductase (DHCR7) in the developmental disorder, Smith-Lemli-Opitz syndrome (SLOS), results in a deficiency in cholesterol and accumulation of its precursor, 7-dehydrocholesterol (7-DHC). Here, we show that loss of DHCR7 causes accumulation of 7-DHC-derived oxysterol metabolites, premature neurogenesis from murine or human cortical neural precursors, and depletion of the cortical precursor pool, both in vitro and in vivo. We found that a major oxysterol, 3ß,5α-dihydroxycholest-7-en-6-one (DHCEO), mediates these effects by initiating crosstalk between glucocorticoid receptor (GR) and neurotrophin receptor kinase TrkB. Either loss of DHCR7 or direct exposure to DHCEO causes hyperactivation of GR and TrkB and their downstream MEK-ERK-C/EBP signaling pathway in cortical neural precursors. Moreover, direct inhibition of GR activation with an antagonist or inhibition of DHCEO accumulation with antioxidants rescues the premature neurogenesis phenotype caused by the loss of DHCR7. These results suggest that GR could be a new therapeutic target against the neurological defects observed in SLOS.


Asunto(s)
Oxidorreductasas actuantes sobre Donantes de Grupo CH-CH , Oxiesteroles , Síndrome de Smith-Lemli-Opitz , Animales , Antioxidantes , Colesterol , Deshidrocolesteroles , Modelos Animales de Enfermedad , Humanos , Ratones , Quinasas de Proteína Quinasa Activadas por Mitógenos , Neurogénesis , Oxidorreductasas , Oxidorreductasas actuantes sobre Donantes de Grupo CH-CH/genética , Oxiesteroles/uso terapéutico , Receptores de Glucocorticoides , Receptores de Factor de Crecimiento Nervioso , Síndrome de Smith-Lemli-Opitz/tratamiento farmacológico , Síndrome de Smith-Lemli-Opitz/genética , Síndrome de Smith-Lemli-Opitz/metabolismo
5.
Eur Spine J ; 26(11): 2763-2772, 2017 11.
Artículo en Inglés | MEDLINE | ID: mdl-28547574

RESUMEN

PURPOSE: The aim of our study was to determine the effect of Oxy133 and rhBMP2 on fusion rates and new bone formation in a rat posterolateral fusion (PLF) model. Furthermore, we examined whether Oxy133 could inhibit the adipogenesis that is often present in rhBMP2-induced fusions. METHODS: Sixty-four male Lewis rats underwent two levels PLF (L3-L5). All animals were randomly divided into eight groups based on the test compound that they received: control (DMSO), low-dose rhBMP2 (0.5 µg), high-dose rhBMP2 (5 µg), low-dose Oxy133 (5 mg), high-dose Oxy133 (20 mg), low rhBMP2 + high Oxy133, high rhBMP2 + high Oxy133, and low rhBMP2 + low Oxy133. Fusion rates were assessed 8 weeks after surgery with manual palpation and plain radiographs. Bone parameters were measured using microCT. Histology was used to evaluate adipogenesis. RESULTS: No fusion was observed in the control group. Based on the manual palpation, 100% fusion was observed in all other groups except in the low-dose rhBMP2 group (69%). At 8 weeks based on X-rays, 100% fusion was observed in the following groups: high-dose rhBMP2, low-dose Oxy133, and low rhBMP2 + low Oxy133. In the other groups, the fusion rates were between 95 and 97%, except for the low rhBMP2 group (72%). We observed similar values in BV/TV ratio at L3-4 when Oxy133 groups were compared to rhBMP2 groups alone (44.62% in high-dose Oxy133 vs. 41.47% in high-dose rhBMP2 and 47.18% in low-dose Oxy133 vs. 54.98% in low-dose rhBMP2). Trabecular thickness was slightly lower in Oxy133 groups compared to rhBMP2 when comparing low- and high-dose groups from each group (118.44 µm for high-dose Oxy133 vs. 122.39 µm for high-dose rhBMP2 and 123.51 µm for low-dose Oxy133 vs. 135.74 µm for low-dose rhBMP2). At the same time, trabecular separation was lower in Oxy133 groups compared to rhBMP2 groups. Similar trends in bone parameters were observed at the L4-5 levels. Fusion masses with low- and high-dose Oxy133 had significantly less adipocytes than rhBMP2 groups that showed robust adipocyte formation. CONCLUSION: In our study, both low-dose and high-dose Oxy133 produced solid fusions with bone densities similar or higher than in the BMP2 groups. High-dose Oxy133 group had significantly less adipocytes than high- or low-dose rhBMP2 groups. Furthermore, high-dose Oxy133 was able to significantly inhibit high-dose BMP2-induced adipogenesis when combined together. Consistent with the previous reports, our preliminary findings suggest that Oxy133 has a significant potential as an alternative to rhBMP2 in spine fusion.


Asunto(s)
Osteogénesis/efectos de los fármacos , Oxiesteroles , Fusión Vertebral/métodos , Esteroles , Animales , Proteína Morfogenética Ósea 2/administración & dosificación , Proteína Morfogenética Ósea 2/farmacología , Masculino , Oxiesteroles/administración & dosificación , Oxiesteroles/farmacología , Oxiesteroles/uso terapéutico , Radiografía , Distribución Aleatoria , Ratas , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/farmacología , Esteroles/administración & dosificación , Esteroles/farmacología , Factor de Crecimiento Transformador beta/administración & dosificación , Factor de Crecimiento Transformador beta/farmacología
6.
Curr Med Chem ; 23(20): 2132-45, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27142287

RESUMEN

Non-cholesterol sterols have been used as markers of cholesterol intestinal absorption and hepatic synthesis, leading to a better understanding of cholesterol homeostasis in humans. This review discusses the main noncholesterol sterols that are clinically useful, different methods to quantify the factors associated with blood concentration, and the potential role of non-cholesterol sterols in the diagnosis and treatment of different types of dyslipidemia. The main indication is the use of non-cholesterol sterols for the diagnosis of rare diseases associated with defects in cholesterol synthesis or anomalies in the absorption and/or elimination of phytosterols. However, other potential uses, including the diagnosis of certain hypercholesterolemias and the individualization of lipid-lowering therapies, are promising as they could help treat a wider population.


Asunto(s)
Dislipidemias/diagnóstico , Dislipidemias/tratamiento farmacológico , Esteroles/metabolismo , Esteroles/uso terapéutico , Ácidos y Sales Biliares/metabolismo , Colesterol/metabolismo , Ezetimiba/uso terapéutico , Humanos , Proteínas de la Membrana/metabolismo , Proteínas de Transporte de Membrana , Oxiesteroles/química , Oxiesteroles/metabolismo , Oxiesteroles/uso terapéutico , Fitosteroles/química , Fitosteroles/metabolismo , Fitosteroles/uso terapéutico , Pravastatina/uso terapéutico , Esteroles/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA